Explorethe depths of your imaging data
Medical images are only the tip of the iceberg. AI-enabled Radiomics allows you to see what's below the surface. Learn more in our Industry Perspectives videos on the value of Radiomics in Clinical Trials. Watch Now
Medical images aren’t just pictures. They’re data to dive into.
Consider that 90% of healthcare data is comprised of medical images, and each image holds quantitative descriptors of tumor structure and lesion characteristics which are not discernible to the human reader. Life science organizations are rudderless with an absence of this critical imaging data to inform clinical trials, monitor therapy response, and drive value-based clinical outcomes.
Explore the Depths of Radiomic Data in Clinical Trials
Watch the HealthMyne and Fierce Biotech interactive panel which explores the depths of radiomic data in clinical trials. Learn how real-world applications and practical strategies for radiomic use in clinical trials, personalized drug development and therapy response.
In this panel, industry thought leaders including Dr. Mimi Huizinga, Dr. Robert Gillies and Dr. Fabien Maldonado shared perspectives from Life Sciences and Academic Research including:
- Challenges and practical strategies for radiomics use
- Real world application of radiomics in research, drug discovery/development and treatment response
- How radiomics can support evolving response evaluation criteria
- The power of combining radiomics, genomics and clinical data to predict patient outcomes and personalize treatment
- How advanced imaging analytics will support biomarker discovery and drive more personalized drug development
Radiomics in Action: Translating Research into Personalized Treatment
Download our ebook to read how radiomics can help you translate research into personalized treatment
When radiomic insights derived from research are applied to individual patients’ treatment plans, clinicians gain insights into disease identification, disease progression and therapy response, and the ability to deliver greater personalization of care.
Without analyzing imaging data, you’re in the dark.
At HealthMyne, we are pioneers in applied radiomics, the cutting-edge field of extracting novel data and biomarkers from medical images. We extract quantitative features or descriptors and convert medical images into mineable data that goes beyond tumor size and burden.
We help life science organizations like yours access and easily translate ground-breaking radiomic insights into use in research, commercial strategies, and personalized health agendas.
We believe Radiomics is the next wave in healthcare, unleashing the hidden power of imaging data to speed drug and treatment development and the achievement of personalized medicine. When combined, radiomics, genomic and clinical data provide a holistic and powerful toolkit for tackling complex disease like cancer.
HealthMyne’s AI-enabled radiomic solution was leveraged in a retrospective study of soft tissue sarcoma patients with lung metastasis
Radiomics-based patient inclusion model improves clinical trail performance. Click below to read the full published research on how HealthMyne’s radiomic solution was leveraged by a leading research organization to determine that quantitative image analysis would have made a difference in clinical trial end points for soft tissue sarcoma patients.
Download our eBook
Seeing Below the Line
Learn how radiomics brings to light previously undiscoverable imaging data and unleashes a wealth of valuable information for life science organizations to evaluate disease progression, monitor therapy response and predict clinical outcomes. Equipped with this powerful information you can create a more precise profile of who is most likely to benefit from individualized therapy in the real world.
Get the Ebook to find out how you can dive deeper into your imaging data and see below the line.
Access our radiomic resources and insights to help guide you.
CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer
A study published in BMC Cancer in 2020 reported that a team from the First Affiliated Hospital of Sun...
Multi-Window CT Based Radiomics Features are Valuable Predictors of Indolent Lung Cancers
Hong Lu, MD and colleagues at Moffitt Cancer Center reported that quantitative radiomic signatures showed the potential to reveal...
Two New Radiomics Features Predict Lung Cancer Survival in Low-Dose CT Screening
Jaileene Perez Morales, MD, of the Moffitt Cancer Center in Tampa, Florida and colleagues identified two predictive radiomic features...
HealthMyne Partners with LuCa on PCP Training for Lung Cancer Care
Primary care provider (PCP) education is essential for impacting lung cancer – the leading cause of cancer death in...
Chapter 6: The Promise of Radiomics
The Long and Short of It Series The use of volume, density and other evidence-based volumetric measurements to define...
Chapter 5: It’s All Very Evident – Other Evidence-Based Metrics
The Long and Short of It Series There is growing recognition and acceptance of volumetrics as a superior method for...
Chapter 4: Depending on Density
The Long and Short of It Series As has been covered in previous chapters, a growing body of evidence suggests...
Chapter 3: The Value of Volume
The Long and Short of It Series Oncologists have relied on Long and Short diameter measurements as a surrogate for...
Chapter 2: Consistency – Reducing Inter- and Intra- Reader Variability
The Long and Short of It Series Accurate and repeatable tumor size measurement is vital in assessing the efficacy of...
Radiomic Solutions for Life Sciences
HealthMyne’s® Radiomic Precision Metrics (RPM) and Radiomic Discovery Services
Our innovative AI and radiomic informed solutions can help your organization curate and digitize data from medical images as well as extract radiomic features to accelerate drug development and deliver real world evidence of therapy response. In addition, radiomic data can enhance and expand existing clinical trials and deliver precise endpoints to inform trial design, inclusion criteria and trial cohorts.
HealthMyne’s Radiomic Informed Therapy Response Module
HealthMyne provides radiomic informed workflow tools for documenting therapy and treatment response, ensuring appropriate clinical protocol assignment, disease progression monitoring and efficiently tracking patients through the trial process.
Analyze Real-World Evidence of Therapy Response
- Inform patient stratification and trial arm assignment
- Potential to increase trial availability
- Incorporate and automate trial protocol and reporting requirements
- Monitor disease progression and response to therapy
Enhance and Expand Existing Clinical Trials
- Incorporate radiomic insights in inclusion criteria and study design
- Leverage more precise and diverse endpoints for improved outcomes
- Measure radiomic data and response to therapy over time
Drive Value-based Clinical Outcomes
- Correlate clinical value and improved patient outcomes with therapy
- Transparency into patient population that will benefit from drug
- Support value-based contracting and reimbursement strategies